SrasV1, PubMed, Checkpoint, bibRecord, 002136

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Identifieur interne : 002136 ( PubMed/Checkpoint ); précédent : 002135; suivant : 002137

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts ; Leen Vijgen ; Herman Egberink ; Erik De Clercq ; Marc Van Ranst ; Svetlana S. Printsevskaya ; Eugenia N. Olsufyeva ; Svetlana E. Solovieva ; Maria N. Preobrazhenskaya

Source :

Antiviral research [ 0166-3542 ] ; 2006.

RBID : pubmed:16675038

Descripteurs français

KwdFr :
- Animaux, Antibactériens (), Antibactériens (pharmacologie), Antibactériens (synthèse chimique), Coronavirus félin (), Coronavirus félin (physiologie), Effet cytopathogène viral (), Glycopeptides (), Glycopeptides (pharmacologie), Glycopeptides (synthèse chimique), Humains, Inactivation virale, Lignée cellulaire, Réplication virale (), Téicoplanine (), Téicoplanine (pharmacologie), Vancomycine (), Vancomycine (pharmacologie), Vancomycine (synthèse chimique), Virus du SRAS (), Virus du SRAS (physiologie).
MESH :
- pharmacologie : Antibactériens, Glycopeptides, Téicoplanine, Vancomycine.
- physiologie : Coronavirus félin, Virus du SRAS.
- synthèse chimique : Antibactériens, Glycopeptides, Vancomycine.
- Animaux, Antibactériens, Coronavirus félin, Effet cytopathogène viral, Glycopeptides, Humains, Inactivation virale, Lignée cellulaire, Réplication virale, Téicoplanine, Vancomycine, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Anti-Bacterial Agents (chemical synthesis), Anti-Bacterial Agents (chemistry), Anti-Bacterial Agents (pharmacology), Cell Line, Coronavirus, Feline (drug effects), Coronavirus, Feline (physiology), Cytopathogenic Effect, Viral (drug effects), Glycopeptides (chemical synthesis), Glycopeptides (chemistry), Glycopeptides (pharmacology), Humans, SARS Virus (drug effects), SARS Virus (physiology), Teicoplanin (chemistry), Teicoplanin (pharmacology), Vancomycin (chemical synthesis), Vancomycin (chemistry), Vancomycin (pharmacology), Virus Inactivation, Virus Replication (drug effects).
MESH :
- chemical , chemical synthesis : Anti-Bacterial Agents, Glycopeptides, Vancomycin.
- chemical , chemistry : Anti-Bacterial Agents, Glycopeptides, Teicoplanin, Vancomycin.
- chemical , pharmacology : Anti-Bacterial Agents, Glycopeptides, Teicoplanin, Vancomycin.
- drug effects : Coronavirus, Feline, Cytopathogenic Effect, Viral, SARS Virus, Virus Replication.
- physiology : Coronavirus, Feline, SARS Virus.
- Animals, Cell Line, Humans, Virus Inactivation.

Abstract

Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC(50)) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC(50) values of the glycopeptide derivatives for FIPV or SARS-CoV.

DOI: 10.1016/j.antiviral.2006.03.005
PubMed: 16675038

Affiliations:

Belgique

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002248
to stream PubMed, to step Curation: 002248

Links to Exploration step

pubmed:16675038

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><nlm:affiliation>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. jan.balzarini@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven</wicri:regionArea>
<wicri:noRegion>B-3000 Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S" last="Printsevskaya">Svetlana S. Printsevskaya</name>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N" last="Olsufyeva">Eugenia N. Olsufyeva</name>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E" last="Solovieva">Svetlana E. Solovieva</name>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N" last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16675038</idno>
<idno type="pmid">16675038</idno>
<idno type="doi">10.1016/j.antiviral.2006.03.005</idno>
<idno type="wicri:Area/PubMed/Corpus">002248</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002248</idno>
<idno type="wicri:Area/PubMed/Curation">002248</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002248</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002136</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002136</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><nlm:affiliation>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. jan.balzarini@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven</wicri:regionArea>
<wicri:noRegion>B-3000 Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S" last="Printsevskaya">Svetlana S. Printsevskaya</name>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N" last="Olsufyeva">Eugenia N. Olsufyeva</name>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E" last="Solovieva">Svetlana E. Solovieva</name>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N" last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Bacterial Agents (chemical synthesis)</term>
<term>Anti-Bacterial Agents (chemistry)</term>
<term>Anti-Bacterial Agents (pharmacology)</term>
<term>Cell Line</term>
<term>Coronavirus, Feline (drug effects)</term>
<term>Coronavirus, Feline (physiology)</term>
<term>Cytopathogenic Effect, Viral (drug effects)</term>
<term>Glycopeptides (chemical synthesis)</term>
<term>Glycopeptides (chemistry)</term>
<term>Glycopeptides (pharmacology)</term>
<term>Humans</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Teicoplanin (chemistry)</term>
<term>Teicoplanin (pharmacology)</term>
<term>Vancomycin (chemical synthesis)</term>
<term>Vancomycin (chemistry)</term>
<term>Vancomycin (pharmacology)</term>
<term>Virus Inactivation</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antibactériens ()</term>
<term>Antibactériens (pharmacologie)</term>
<term>Antibactériens (synthèse chimique)</term>
<term>Coronavirus félin ()</term>
<term>Coronavirus félin (physiologie)</term>
<term>Effet cytopathogène viral ()</term>
<term>Glycopeptides ()</term>
<term>Glycopeptides (pharmacologie)</term>
<term>Glycopeptides (synthèse chimique)</term>
<term>Humains</term>
<term>Inactivation virale</term>
<term>Lignée cellulaire</term>
<term>Réplication virale ()</term>
<term>Téicoplanine ()</term>
<term>Téicoplanine (pharmacologie)</term>
<term>Vancomycine ()</term>
<term>Vancomycine (pharmacologie)</term>
<term>Vancomycine (synthèse chimique)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Teicoplanin</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Teicoplanin</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus, Feline</term>
<term>Cytopathogenic Effect, Viral</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antibactériens</term>
<term>Glycopeptides</term>
<term>Téicoplanine</term>
<term>Vancomycine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus félin</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus, Feline</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antibactériens</term>
<term>Glycopeptides</term>
<term>Vancomycine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Humans</term>
<term>Virus Inactivation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antibactériens</term>
<term>Coronavirus félin</term>
<term>Effet cytopathogène viral</term>
<term>Glycopeptides</term>
<term>Humains</term>
<term>Inactivation virale</term>
<term>Lignée cellulaire</term>
<term>Réplication virale</term>
<term>Téicoplanine</term>
<term>Vancomycine</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC(50)) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC(50) values of the glycopeptide derivatives for FIPV or SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16675038</PMID>
<DateCompleted><Year>2006</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN>
<JournalIssue CitedMedium="Print"><Volume>72</Volume>
<Issue>1</Issue>
<PubDate><Year>2006</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.</ArticleTitle>
<Pagination><MedlinePgn>20-33</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC(50)) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC(50) values of the glycopeptide derivatives for FIPV or SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balzarini</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. jan.balzarini@rega.kuleuven.be</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Keyaerts</LastName>
<ForeName>Els</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vijgen</LastName>
<ForeName>Leen</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Egberink</LastName>
<ForeName>Herman</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Clercq</LastName>
<ForeName>Erik</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Van Ranst</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Printsevskaya</LastName>
<ForeName>Svetlana S</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Olsufyeva</LastName>
<ForeName>Eugenia N</ForeName>
<Initials>EN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Solovieva</LastName>
<ForeName>Svetlana E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Preobrazhenskaya</LastName>
<ForeName>Maria N</ForeName>
<Initials>MN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2006</Year>
<Month>04</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006020">Glycopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>110865-90-2</RegistryNumber>
<NameOfSubstance UI="C053759">eremomycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>61036-62-2</RegistryNumber>
<NameOfSubstance UI="D017334">Teicoplanin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6Q205EH1VU</RegistryNumber>
<NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016765" MajorTopicYN="N">Coronavirus, Feline</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006020" MajorTopicYN="N">Glycopeptides</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017334" MajorTopicYN="N">Teicoplanin</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014640" MajorTopicYN="N">Vancomycin</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D038301" MajorTopicYN="N">Virus Inactivation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>01</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2006</Year>
<Month>03</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>03</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16675038</ArticleId>
<ArticleId IdType="pii">S0166-3542(06)00072-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2006.03.005</ArticleId>
<ArticleId IdType="pmc">PMC7114212</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Med Chem. 1989 Nov;32(11):2450-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2530352</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1986 Oct;39(10):1430-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2946651</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1997 Jun;50(6):509-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9268008</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1993 Nov;46(11):1731-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8270496</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1989 Aug;42(8):1268-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2527218</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1990 Sep;43(9):1107-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2145253</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 1992 Oct 30;35(22):4054-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1433211</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1996 Nov;49(11):1157-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8982345</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1996 Feb;49(2):194-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8621361</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2003 Mar 27;46(7):1204-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12646030</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 2000 Mar;53(3):286-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10819300</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1993 Jul 16;261(5119):308-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8392747</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2002 Mar 14;45(6):1340-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11882003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2005 Aug 15;15(16):3801-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15993054</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1996 Dec;49(12):1236-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9031670</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1998 Jan;51(1):73-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9531990</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2003 Jun 19;46(13):2755-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12801238</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1996 Dec;70(12):8669-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8970993</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1987 Nov;40(11):1572-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2961722</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 2001 May;54(5):455-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11480890</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2005 Jun 2;48(11):3885-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15916441</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antibiot Khimioter. 1991 Jun;36(6):28-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1910324</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 1988 Aug;20(4):309-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2460479</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1999 Mar;52(3):319-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10348049</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1989 Jan;42(1):63-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2921228</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1994 Feb;47(2):225-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8150719</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1993 Aug;46(8):1181-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8407579</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antibiot (Tokyo). 1987 Jan;40(1):49-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2951359</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antimicrob Chemother. 2006 Mar;57(3):472-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16387746</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Belgique</li>
</country>
</list>
<tree><noCountry><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N" last="Olsufyeva">Eugenia N. Olsufyeva</name>
<name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N" last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S" last="Printsevskaya">Svetlana S. Printsevskaya</name>
<name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E" last="Solovieva">Svetlana E. Solovieva</name>
<name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</noCountry>
<country name="Belgique"><noRegion><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002136 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002136 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:16675038
   |texte=   Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:16675038" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki